Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENICAR vs BYVALSON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
Treatment of hypertension in adults and children ≥6 years,Off-label: Diabetic nephropathy, heart failure
FDA-approved for the treatment of hypertension, heart failure (NYHA class II-IV), and to reduce cardiovascular mortality in stable post-myocardial infarction patients with left ventricular dysfunction or failure.,Off-label uses include diabetic nephropathy, prevention of atrial fibrillation recurrence, and migraine prophylaxis.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
160 mg orally once daily.
Terminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Prodrug olmesartan medoxomil is rapidly hydrolyzed to active olmesartan by esterases in gastrointestinal tract. Olmesartan is not metabolized by CYP450 enzymes and is excreted unchanged in bile and urine.
Valsartan is primarily metabolized by CYP2C9 and minimally by CYP3A4. It undergoes glucuronidation via UGT1A3, UGT1A9, and UGT2B7. The major metabolite is inactive.
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Highly protein-bound (approximately 99%) to serum albumin.
95% bound primarily to albumin
Volume of distribution is approximately 17 L (0.2–0.3 L/kg), indicating limited extravascular distribution.
Vd 8-10 L/kg; suggests extensive extravascular distribution
Oral bioavailability is about 26–29% (absolute).
Oral: 50% (range 40-60%); food reduces peak concentration but not AUC
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initial dose 20 mg once daily; maximum 40 mg/day.
No dosage adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min.
No adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe impairment (Child-Pugh C).
Contraindicated in severe hepatic impairment (Child-Pugh class C); no adjustment for mild to moderate impairment (Child-Pugh A or B).
Safety and efficacy not established for pediatric patients <18 years.
Safety and efficacy not established in pediatric patients.
Initial 20 mg once daily; caution due to potential for reduced renal function. Monitor BP and electrolytes.
No specific dose adjustment recommended; initiate cautiously due to potential for decreased renal function.
No FDA black box warning.
Fetal toxicity: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal malformations, oligohydramnios, and neonatal renal failure. Discontinue as soon as pregnancy is detected.
May cause fetal harm if used during pregnancy,Avoid use in patients with severe renal impairment (Cr Cl <20 m L/min),Sprue-like enteropathy (severe chronic diarrhea with weight loss),Hypotension in volume-depleted patients,Hyperkalemia,Renal function deterioration in patients with renal artery stenosis
Hypotension in volume- or salt-depleted patients,Hyperkalemia, especially with renal impairment, diabetes, or concomitant potassium-sparing diuretics,Renal function impairment, including acute renal failure,Angioedema (rare),Use caution in severe aortic stenosis,Avoid concomitant use with aliskiren in diabetic patients
Concomitant use with aliskiren in patients with diabetes mellitus,History of hypersensitivity to any component of the product
Pregnancy (absolute),History of angioedema from any ARB or ACE inhibitor,Concomitant use with aliskiren in diabetic patients (absolute),Severe hepatic impairment (Child-Pugh class C) (relative)
No significant food interactions; may be taken with or without food. However, avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) if renal impairment is present or if taking potassium supplements.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium chloride, as BYVALSON can increase potassium levels.
Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data are limited. Use in the second and third trimesters is known to cause fetal renal dysfunction, oligohydramnios, skull ossification deficits, and neonatal hypotension, hyperkalemia, and renal failure.
Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypotension. Risk is highest in the second and third trimesters; first-trimester exposure may also increase risk of congenital malformations.
Minimal excretion into breast milk; M/P ratio is unknown. The American Academy of Pediatrics considers use compatible with breastfeeding, but caution is advised in preterm infants or those with renal impairment.
No data on Byvalson (valsartan/nebivolol) in breast milk. Valsartan is excreted in rat milk; unknown in humans. Nebivolol is likely excreted in human milk. Due to potential for adverse effects in nursing infants (hypotension, bradycardia), breastfeeding is not recommended. M/P ratio not established.
No dose adjustment typically required in pregnancy, but pharmacokinetic changes (increased volume of distribution, altered renal clearance) may necessitate careful blood pressure monitoring and dose titration. Avoid use during second and third trimesters if possible.
Byvalson is contraindicated in pregnancy; no dose adjustment is recommended. Alternative antihypertensives with established safety profiles should be used. If exposure occurs, discontinue immediately and manage with appropriate therapy.
BENICAR (olmesartan) is an angiotensin II receptor blocker (ARB) used primarily for hypertension. It demonstrates a dose-dependent antihypertensive effect with a once-daily dosing regimen. Monitor renal function and serum potassium, especially in patients with renal impairment or those on potassium-sparing diuretics. Avoid use in pregnancy (category D).
BYVALSON (sacubitril/valsartan) is a first-in-class ARNI approved for heart failure with reduced ejection fraction (HFr EF). Monitor blood pressure and renal function closely upon initiation, especially in patients on high-dose ACE inhibitors or ARBs. Avoid use with ACE inhibitors within 36 hours due to risk of angioedema. May cause hypotension, hyperkalemia, and renal impairment. Titrate every 2-4 weeks to target dose of 97/103 mg BID as tolerated.
Take exactly as prescribed, usually once daily with or without food.,It may take 2-4 weeks to see full blood pressure lowering effect.,Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium (muscle weakness, slow heartbeat) or low blood pressure (dizziness, fainting).,Stay hydrated but avoid excessive dehydration (e.g., from diarrhea or vomiting).,Do not abruptly stop this medication without consulting your doctor.
Do not take within 36 hours of any ACE inhibitor medication.,Take BYVALSON twice daily with or without food.,Monitor blood pressure regularly; report dizziness or fainting.,Avoid salt substitutes containing potassium.,Seek medical help immediately if you experience swelling of the face, lips, or throat.,Stay hydrated but do not use potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENICAR vs BYVALSON, answered by our medical review team.
BENICAR is a Angiotensin II Receptor Blocker that works by Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.. BYVALSON is a Angiotensin II Receptor Blocker that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENICAR and BYVALSON depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENICAR is: Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.. The standard adult dose of BYVALSON is: 160 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENICAR and BYVALSON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENICAR is classified as Category C. Pregnancy Category C (first trimester) and D (second and third trimesters). Exposure during the first trimester is associated with a potential risk of teratogenicity, though data a. BYVALSON is classified as Category C. Angiotensin II receptor antagonists (ARBs) are contraindicated in pregnancy due to fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal anuria/hypoten. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.